Investor Presentations
Presentation material used for investor briefings is posted below after release to the Australian Securities Exchange.
Investor Presentation - 29 April 2022
Updated investor presentation
View presentation – pdfPharmaxis R&D Showcase Webinars - Recordings
Pharmaxis Ltd recently hosted R&D Showcase Webinars for each of the Company’s two lead drug discoveries. Presentations by globally renowned clinicians and scientists involved in the Company’s clinical programs were followed by Q&A sessions spearheaded by selected panels of biotech analysts and fund managers. The webinars were moderated by Michael Woods.
Showcase Webinar #1: Pharmaxis Drug PXS-5505 Targeting Several Cancers.
Presentation |
Speaker |
Link to recording |
Welcome and Introduction to Pharmaxis research and clinical development program |
Michael Woods Dr Wolfgang Jarolimek Gary Phillips |
|
The myelofibrosis landscape and MF-101 |
Dr Gabriela Hobbs (Massachusetts General Hospital) |
|
Hepatocellular cancer and Rochester University investigator led study |
Dr Paul Burchard (Rochester NY) |
|
Pancreatic Cancer |
Dr Tom Cox |
|
Pharmaxis Q&A |
Gary Phillips |
Panel members: Hashan Da Silva (Karst Peak), Bianca Ogden (Platinum), Dennis Hulme (Taylor Collison) and Derek Jellinek (Morgans)
A pdf of the presentations is available here.
Showcase Webinar #2: Pharmaxis Drug PXS-6302 Designed to Target Skin Scarring.
Presentation |
Speaker |
Link to recording |
Welcome and Introduction to Pharmaxis – a global leader in lysyl oxidase chemistry and biology |
Gary Phillips |
|
The science of scarring and potential for LOX inhibition |
Dr Mark Fear (UWA) |
|
Clinical applications for LOX inhibition |
Professor Fiona Wood (UWA) |
|
Q&A with panel |
Panel members: Scott Power (Morgan), David Nayagam (Evans and Partners) and Chris Kallos (MST Access)
A pdf of the presentations is available here.